Pharmaceutical

Amylyx ventures into metabolic diseases market with $35.1m deal

On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.

Jun 30, 2024 - 04:00
Amylyx ventures into metabolic diseases market with $35.1m deal
On 17 June, Amylyx acquired the rights to Eiger Biopharmaceutical’s experimental GLP-1 receptor antagonist, avexitide, for $35.1m.
Read the original article

Tags:

Previous Article

Supreme Court votes against Purdue Pharma’s opioid settlement

Next Article

Coherus offloads Humira biosimilar Yusimry for $40m

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: ‘Hard to catch up’: FDA commissioner on regulating new digital health tools

STAT+: ‘Hard to catch up’: FDA commissioner on regulati...

May 9, 2023

STAT+: Medical leaders decry Supreme Court decision on affirmative action

STAT+: Medical leaders decry Supreme Court decision on ...

Jul 2, 2023

Meitheal partners with Chinese company for US licencing of insulin biosimilars

Meitheal partners with Chinese company for US licencing...

Sep 21, 2023